Published in J Control Release on October 14, 2016
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Cancer genome landscapes. Science (2013) 25.33
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science (2011) 15.45
Comprehensive human genome amplification using multiple displacement amplification. Proc Natl Acad Sci U S A (2002) 13.58
5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer (2003) 11.78
mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods (2009) 11.71
Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol (2006) 9.58
CpG islands and the regulation of transcription. Genes Dev (2011) 9.50
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 8.93
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Regulation of alternative splicing by histone modifications. Science (2010) 7.98
Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol (2011) 7.84
Microfluidic large-scale integration. Science (2002) 7.64
Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet (2010) 7.39
Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol (2012) 7.37
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27
Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A (2009) 6.91
Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell (2009) 6.54
Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature (2013) 6.50
Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell (2015) 6.38
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 6.12
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell (2012) 5.62
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med (2012) 5.31
CEL-Seq: single-cell RNA-Seq by multiplexed linear amplification. Cell Rep (2012) 5.17
Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell (2012) 5.16
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet (2001) 5.08
Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol (2011) 4.48
Integrative analysis of the cancer transcriptome. Nat Genet (2005) 4.44
Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell (2015) 4.42
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun (2005) 4.06
Tumour heterogeneity in the clinic. Nature (2013) 3.92
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol (2012) 3.86
THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. Cancer Res (1963) 3.74
VEGF as a key mediator of angiogenesis in cancer. Oncology (2005) 3.65
A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol (2008) 3.59
Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther (2005) 3.28
Network-based stratification of tumor mutations. Nat Methods (2013) 3.12
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem (2008) 2.89
Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell (2011) 2.87
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res (2008) 2.76
Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer (1995) 2.64
Inherited susceptibility to common cancers. N Engl J Med (2008) 2.54
Multiplexed ion beam imaging of human breast tumors. Nat Med (2014) 2.40
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet (2000) 2.31
Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet (1997) 2.23
Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem (1996) 2.17
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab (2009) 2.17
Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med (2012) 2.13
Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer (2006) 2.13
Overexpression of folate binding protein in ovarian cancers. Int J Cancer (1997) 2.13
Folate-targeted chemotherapy. Adv Drug Deliv Rev (2004) 2.04
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol (2013) 1.92
Significance of multiple mutations in cancer. Carcinogenesis (2000) 1.86
The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol (2008) 1.86
Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res (2003) 1.86
Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev (2014) 1.78
Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer (1997) 1.72
Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond) (2008) 1.67
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol (2009) 1.66
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol (2006) 1.65
ErbB-3 predicts survival in ovarian cancer. J Clin Oncol (2006) 1.64
Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A (2005) 1.60
The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) (2015) 1.59
A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer (2009) 1.59
Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release (2009) 1.54
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res (2007) 1.49
Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics (2011) 1.46
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest (2016) 1.45
Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics. Proc Natl Acad Sci U S A (2002) 1.43
Next-generation sequencing: methodology and application. J Invest Dermatol (2013) 1.34
Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release (2003) 1.31
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther (2015) 1.19
Quantitative real-time PCR for cancer detection: the lymphoma case. Expert Rev Mol Diagn (2005) 1.18
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol (2013) 1.18
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. Cell (2016) 1.17
Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer (2007) 1.15
New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med (2015) 1.12
Folate and antifolate pharmacology. Semin Oncol (1997) 1.12
The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol (Dordr) (2011) 1.10
A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. Ann Oncol (2001) 1.09
A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol (2009) 1.07
Targeted proapoptotic LHRH-BH3 peptide. Pharm Res (2003) 1.05
Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett (2006) 1.05
Single-Cell Analysis in Cancer Genomics. Trends Genet (2015) 1.05
Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol (2007) 1.02